Modification of Cue Reactivity by Neurofeedback in Human Addiction

NCT ID: NCT04366505

Last Updated: 2021-04-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

88 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-01

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The project is geared towards the understanding of how to increase cognitive control over cue reactivity and drug craving.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Project C04 aims at assessing the combined effect of two interventions targeting at reducing striatal cue reactivity and increasing cognitive control, namely mindfulness-based intervention and real-time fMRI neurofeedback. Firstly, the investigators will test whether a prior mindfulness-based intervention (WP1) is able to enhance the effect of rtfMRI NFB (WP2) and change the networks involved in regulation of cue reactivity by providing participants with explicit strategies. Secondly, the investigators will investigate whether this combined intervention leads to a better clinical outcome in terms of decreased heavy drinking days and a reduced sum of alcohol consumption three months later.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol Use Disorder (AUD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
The participants will be allocated to one of two NFB groups (real NFB or control group) in a double-blind procedure.

Participants of both groups will be further sub-divided into a mindfulness-based relapse prevention (MBRP) and a TAU group (single-blind).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NFB + (MBRP)

Neurofeedback (NFB) from target region or control region plus Mindfulness-based relapse prevention (for some)

Group Type EXPERIMENTAL

Treatment as usual (TAU) and neurofeedback (NFB)

Intervention Type BEHAVIORAL

This group will receive Treatment as usual (TAU) and neurofeedback (NFB). During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as target region.

mindfulness-based relapse prevention (MBRP) and NFB

Intervention Type BEHAVIORAL

This group will receive MBRP and neurofeedback (NFB). MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as a target region.

MBT and sham NFB

Intervention Type BEHAVIORAL

This group will receive MBRP and sham NFB. MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.

TAU and sham NFB

TAU + Neurofeedback (NFB) from control region

Group Type ACTIVE_COMPARATOR

TAU and sham NFB

Intervention Type BEHAVIORAL

This group will receive TAU and sham NFB. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treatment as usual (TAU) and neurofeedback (NFB)

This group will receive Treatment as usual (TAU) and neurofeedback (NFB). During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as target region.

Intervention Type BEHAVIORAL

mindfulness-based relapse prevention (MBRP) and NFB

This group will receive MBRP and neurofeedback (NFB). MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as a target region.

Intervention Type BEHAVIORAL

TAU and sham NFB

This group will receive TAU and sham NFB. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.

Intervention Type BEHAVIORAL

MBT and sham NFB

This group will receive MBRP and sham NFB. MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* alcohol use disorder according to DSM-5
* ability to provide fully informed consent and to use self-rating scales
* abstinent after detoxification for at least 5 days
* sufficient understanding of the German language

Exclusion Criteria

* lifetime history of DSM-5 bipolar, psychotic disorder, or substance dependence other than alcohol or nicotine dependence
* current substance use other than nicotine and/or mild to moderate recreational use of cannabis as evidenced by positive urine test
* current threshold DSM-5 diagnosis of any of the following disorders: current (hypo)manic episode, major depressive disorder, generalized anxiety disorder, PTSD, borderline personality disorder, or obsessive compulsive disorder
* history of severe head trauma or other severe central neurological disorders (dementia, Parkinson's disease, multiple sclerosis)
* pregnancy or nursing infants
* use of medications or drugs known to interact with the CNS within the last 10 days, with testing at least four half-lives post last intake
Minimum Eligible Age

21 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Central Institute of Mental Health, Mannheim

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Klinische Psychologie + Klinik für Abhängiges Verhalten und Suchtmedizin, Zentralinstitut für Seelische Gesundheit

Mannheim, Baden-Wurttemberg, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Peter Kirsch, Prof. Dr.

Role: CONTACT

+49-621/1703 ext. 6501

Falk Kiefer, Prof. Dr.

Role: CONTACT

+49-621/1703 ext. 3501

References

Explore related publications, articles, or registry entries linked to this study.

Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995 Feb;19(1):92-9. doi: 10.1111/j.1530-0277.1995.tb01475.x.

Reference Type BACKGROUND
PMID: 7771669 (View on PubMed)

DiClemente CC, Carbonari JP, Montgomery RP, Hughes SO. The Alcohol Abstinence Self-Efficacy scale. J Stud Alcohol. 1994 Mar;55(2):141-8. doi: 10.15288/jsa.1994.55.141.

Reference Type BACKGROUND
PMID: 8189734 (View on PubMed)

Bohn MJ, Krahn DD, Staehler BA. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res. 1995 Jun;19(3):600-6. doi: 10.1111/j.1530-0277.1995.tb01554.x.

Reference Type BACKGROUND
PMID: 7573780 (View on PubMed)

Weiss F, Aslan A, Zhang J, Gerchen MF, Kiefer F, Kirsch P. Using mind control to modify cue-reactivity in AUD: the impact of mindfulness-based relapse prevention on real-time fMRI neurofeedback to modify cue-reactivity in alcohol use disorder: a randomized controlled trial. BMC Psychiatry. 2020 Jun 16;20(1):309. doi: 10.1186/s12888-020-02717-7.

Reference Type DERIVED
PMID: 32546139 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TRR265 C04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Methamphetamine Cue-reactivity
NCT07086014 RECRUITING
Cocaine Use Disorder and Cortical Dopamine
NCT03349606 COMPLETED EARLY_PHASE1
Craving & Decision-Making
NCT06440577 RECRUITING NA